KR20230047140A - 알츠하이머병 치료를 위한 n'-(2-클로로-6-메틸벤조일)-4-메틸-3-[2-(3-퀴놀릴)에티닐]-벤조히드라지드 - Google Patents

알츠하이머병 치료를 위한 n'-(2-클로로-6-메틸벤조일)-4-메틸-3-[2-(3-퀴놀릴)에티닐]-벤조히드라지드 Download PDF

Info

Publication number
KR20230047140A
KR20230047140A KR1020237006846A KR20237006846A KR20230047140A KR 20230047140 A KR20230047140 A KR 20230047140A KR 1020237006846 A KR1020237006846 A KR 1020237006846A KR 20237006846 A KR20237006846 A KR 20237006846A KR 20230047140 A KR20230047140 A KR 20230047140A
Authority
KR
South Korea
Prior art keywords
methylbenzoyl
quinolyl
chloro
methyl
ethynyl
Prior art date
Application number
KR1020237006846A
Other languages
English (en)
Korean (ko)
Inventor
니틴 크리슈나지 다믈레
산제이 난들랄히 만다네
두르게시 아쇽쿠마르 소니
샤크티 카말찬드 제인
비크람 크리슈나 라마나탄
Original Assignee
썬 파마 어드밴스트 리서치 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썬 파마 어드밴스트 리서치 컴패니 리미티드 filed Critical 썬 파마 어드밴스트 리서치 컴패니 리미티드
Publication of KR20230047140A publication Critical patent/KR20230047140A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237006846A 2020-07-31 2021-07-30 알츠하이머병 치료를 위한 n'-(2-클로로-6-메틸벤조일)-4-메틸-3-[2-(3-퀴놀릴)에티닐]-벤조히드라지드 KR20230047140A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021032951 2020-07-31
IN202021032951 2020-07-31
PCT/IB2021/056986 WO2022024072A1 (en) 2020-07-31 2021-07-30 N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20230047140A true KR20230047140A (ko) 2023-04-06

Family

ID=77265130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006846A KR20230047140A (ko) 2020-07-31 2021-07-30 알츠하이머병 치료를 위한 n'-(2-클로로-6-메틸벤조일)-4-메틸-3-[2-(3-퀴놀릴)에티닐]-벤조히드라지드

Country Status (12)

Country Link
US (1) US20230301982A1 (ja)
EP (1) EP4188351A1 (ja)
JP (1) JP2023536440A (ja)
KR (1) KR20230047140A (ja)
CN (1) CN116194098A (ja)
AU (1) AU2021317186A1 (ja)
BR (1) BR112023001330A2 (ja)
CA (1) CA3185939A1 (ja)
CL (1) CL2023000270A1 (ja)
IL (1) IL300044A (ja)
MX (1) MX2023001358A (ja)
WO (1) WO2022024072A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101892574B1 (ko) 2011-01-21 2018-08-28 썬 파마 어드밴스트 리서치 컴패니 리미티드 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
AU2017273415B2 (en) 2016-06-02 2023-01-19 Sun Pharma Advanced Research Company Limited Treatment for Parkinson's disease
CN110494422A (zh) * 2017-03-15 2019-11-22 太阳制药先进研究有限公司 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体

Also Published As

Publication number Publication date
AU2021317186A1 (en) 2023-03-16
CN116194098A (zh) 2023-05-30
EP4188351A1 (en) 2023-06-07
US20230301982A1 (en) 2023-09-28
MX2023001358A (es) 2023-02-27
IL300044A (en) 2023-03-01
BR112023001330A2 (pt) 2023-02-14
CL2023000270A1 (es) 2023-09-29
JP2023536440A (ja) 2023-08-25
CA3185939A1 (en) 2022-02-03
WO2022024072A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
JP5933258B2 (ja) ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物
Ridolo et al. Bilastine: new insight into antihistamine treatment
Oertel et al. Parkinsonism
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
KR20140038378A (ko) 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
PT2282779E (pt) Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular
TWI535441B (zh) 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成
KR20170122777A (ko) 트라디피턴트에 의한 치료 방법
CA3136633A1 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
AU2004298393A1 (en) Copper antagonist compounds
EP1732549A2 (en) Methods for the treatment of synucleinopathies
KR20230047140A (ko) 알츠하이머병 치료를 위한 n'-(2-클로로-6-메틸벤조일)-4-메틸-3-[2-(3-퀴놀릴)에티닐]-벤조히드라지드
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
TW201618760A (zh) 使用半胱胺組合物治療亨廷頓氏病之方法
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
JP2008501656A (ja) β−アミロイド（Ａβ４０及びＡβ４２）生成阻害のためのモノアミン神経伝達物質再取り込み阻害剤
OA21248A (en) N'-(2-Chloro-6-Methylbenzoyl)-4-Methyl-3[2-(3-Quinolyl) Ethynyl]-Benzohydrazide for treatment of Alzheimer's disease.
TW201609640A (zh) 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
JP2022535929A (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
JP7271437B2 (ja) Ｎｋ１拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法
JP2010529125A (ja) 胃食道逆流疾患の治療に有用な組成物
JP2014037445A (ja) 抵抗性統合失調症およびその他のｃｎｓ疾患の治療
RU2799049C2 (ru) Способы лечения изменений поведения